Results from a 26-patient prospective multi-center study suggest that Moximed’s Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a next-generation knee joint unloader for pre-arthroplasty patients, and builds on technology from the company’s KineSpring® implantable device designed to unload weight on osteoarthritic knee joints.
Results from a 26-patient prospective multi-center study suggest that Moximed's Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a...
Results from a 26-patient prospective multi-center study suggest that Moximed’s Atlas™ knee provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Atlas obtained CE Mark approval in 4Q15. Early EU launch is underway. The system is described as a next-generation knee joint unloader for pre-arthroplasty patients, and builds on technology from the company’s KineSpring® implantable device designed to unload weight on osteoarthritic knee joints.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
